Advances in Nonmetastatic Castrate-Resistant Prostate Cancer (and High-Risk Disease)

In this downloadable slideset, David F. Penson, MD, reviews the latest evidence and guidelines supporting the optimal management of patients with nonmetastatic castration-resistant prostate cancer.
David F. Penson, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 1.59 MB
Released: May 3, 2019

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by independent educational grants from
Astellas
Pfizer, Inc.

Related Content

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

From Clinical Care Options (CCO), experts discuss advances in prostate cancer treatment, including use of GnRH antagonists and androgen receptor inhibitors.

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD, MPH Released: November 2, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue